We found a 100% concordance in KRAS mutations in a small tumor cohort including a sample with wild-type KRAS. The lowest frequency in the mutation to wild-type in these patients was 0.82% (mutation allele frequency in the primary tumor lesion was 12.8%; Table1). Here, KRAS is linked to neoplasm.